However, Stoop et al. suggested that upregulated CHI3L1 levels might not be a specific marker for inflammatory processes in MS correlated with disease activity and progression, but might be the result of inflammation in CNS irrespective of disease [98]. This evidence concerns the gene CHI3L1 and myeloid sarcoma.